GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 186.3 BRL | +1.07% |
|
+2.29% | -3.25% |
| Jul. 11 | Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78 | MT |
| Jul. 09 | RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating | MT |
| Sales 2024 * | 27.58B 150B | Sales 2025 * | 27.96B 152B | Capitalization | 87.16B 473B |
|---|---|---|---|---|---|
| Net income 2024 * | 387M 2.1B | Net income 2025 * | 6.3B 34.23B | EV / Sales 2024 * | 3.82 x |
| Net Debt 2024 * | 18.29B 99.31B | Net Debt 2025 * | 13.44B 72.98B | EV / Sales 2025 * | 3.6 x |
| P/E ratio 2024 * |
205
x | P/E ratio 2025 * |
13.5
x | Employees | 18,000 |
| Yield 2024 * |
4.43% | Yield 2025 * |
4.7% | Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
| 1 day | +1.07% | ||
| 1 week | +2.29% | ||
| Current month | -2.69% | ||
| 1 month | +7.52% | ||
| 3 months | +7.15% | ||
| 6 months | -10.62% | ||
| Current year | -3.25% |
1 week
182.23
187.56
1 month
174.70194.55
Current year
163.57215.96
1 year
163.57215.96
3 years
132.24235.55
5 years
122.30238.80
10 years
102.29238.80
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-11 | 186.3 | +1.07% | 175 |
| 24-07-10 | 184.3 | +1.14% | 300 |
| 24-07-09 | 182.2 | -1.62% | 6 |
| 24-07-08 | 185.2 | +1.72% | 268 |
Delayed Quote Sao Paulo, July 11, 2024 at 10:04 am EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.96
USD
Average target price
83.08
USD
Spread / Average Target
+18.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +62.66% | 854B | |
| +40.42% | 636B | |
| -4.37% | 361B | |
| +17.16% | 324B | |
| +9.87% | 301B | |
| +15.66% | 247B | |
| +4.21% | 230B | |
| +17.90% | 228B | |
| +14.86% | 177B |
- Stock Market
- Equities
- GILD Stock
- GILD34 Stock
